ORIC Pharmaceuticals, Inc.
Financials
Valuation Metrics
ORIC Pharmaceuticals, Inc.'s Market Cap is $1.32B. At end of 2025 it was $718M. Ranked #2304 of 3,121 in US market (top 74%), #929 of 1,463 on NASDAQ (top 63%), #174 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.32B | US#2,304/3,121 Sec#174/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-140M | US—/3,121 Sec—/266 |
| Total Assets | $405M | US#2,842/3,121 Sec#186/266 |
| Net Assets | $381M | US#2,404/3,121 Sec#140/266 |
| Employees | 111 | US#2,606/3,121 Sec#170/266 |
| Value | ||
| P/B | 3.47x | US#1,891/3,121 Sec#99/266 |
| FCF Yield | -8.49% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -36.81% | US#2,609/3,121 Sec#125/266 |
| ROA | -34.68% | US#2,917/3,121 Sec#170/266 |
| Financial Health | ||
| Debt Ratio | 6.15% | US#53/3,121 Sec#23/266 |
| Total Debt | $3M | US#2,941/3,121 Sec#228/266 |
| FCF | $-112M | US#2,654/3,121 Sec#153/266 |
| Cash | $37M | US#2,696/3,121 Sec#241/266 |
| Current Ratio | 13.19x | US#192/3,121 Sec#60/266 |
| Performance | ||
| 1Y Return | 16.27% | US#1,099/3,121 Sec#151/266 |
| 1M Return | -12.70% | US#2,126/3,121 Sec#161/266 |
| From 52W High | -14.33% | US#1,019/3,121 Sec#71/266 |
| 1Y MDD | -48.09% | US#2,371/3,121 Sec#171/266 |
| Trading | ||
| Volume | 2,732,154 shares | US#1,294/3,121 Sec#137/266 |
| Trading Value | $35M | US#2,109/3,121 Sec#167/266 |
| Per Share | ||
| EPS | $-1.36 | US—/3,121 Sec—/266 |
| BPS | $3.68 | US#2,403/3,121 Sec#148/266 |
Company Info
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.